Bromocriptine-QR is a unique quick release formulation of micronized bromocriptine, a potent dopamine D2 receptor agonist, which is FDA-approved to treat type 2 diabetes (T2D), indicated to be administered within 2 h of waking in the morning (the onset of daily locomotor activity and the natural peak of CNS dopaminergic activity) [12]. This evidence concerns the gene DRD2 and type 2 diabetes mellitus.